Promoting Remyelination in Multiple Sclerosis

Overview

Journal J Neurol

Specialty Neurology

Date 2019 Jun 14

PMID 31190170

Citations 63

Authors

Nick Cunniffe

Alasdair Coles

Affiliations

Soon will be listed here.

Abstract

The greatest unmet need in multiple sclerosis (MS) are treatments that delay, prevent or reverse progression. One of the most tractable strategies to achieve this is to therapeutically enhance endogenous remyelination; doing so restores nerve conduction and prevents neurodegeneration. The biology of remyelination-centred on the activation, migration, proliferation and differentiation of oligodendrocyte progenitors-has been increasingly clearly defined and druggable targets have now been identified in preclinical work leading to early phase clinical trials. With some phase 2 studies reporting efficacy, the prospect of licensed remyelinating treatments in MS looks increasingly likely. However, there remain many unanswered questions and recent research has revealed a further dimension of complexity to this process that has refined our view of the barriers to remyelination in humans. In this review, we describe the process of remyelination, why this fails in MS, and the latest research that has given new insights into this process. We also discuss the translation of this research into clinical trials, highlighting the treatments that have been tested to date, and the different methods of detecting remyelination in people.

Citing Articles

Emerging therapeutic application of clemastine: a review of recent patents updates.

Soni S, Kaur G Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40055203 DOI: 10.1007/s00210-025-03978-3.

Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Boost Functional Performance in an Animal Model of Multiple Sclerosis Through Recruiting Oligodendrocytes and Attenuating Gliosis.

Mirab S, Omidi A, Soleimani M, Soufi-Zomorrod M, Fekrirad Z Stem Cell Rev Rep. 2025; .

PMID: 40053309 DOI: 10.1007/s12015-025-10858-z.

Exploratory analysis of biological age measures in a remyelination clinical trial.

McMurran C, de Meo E, Cunniffe N, Brown J, Prados F, Kanber B Brain Commun. 2025; 7(1):fcaf032.

PMID: 40008332 PMC: 11852336. DOI: 10.1093/braincomms/fcaf032.

Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress.

Ricigliano V, Marenna S, Borrelli S, Camera V, Carnero Contentti E, Szejko N Biomedicines. 2025; 13(2).

PMID: 40002770 PMC: 11853245. DOI: 10.3390/biomedicines13020357.

APOEε4 alters ApoE and Fabp7 in frontal cortex white matter in prodromal Alzheimer's disease.

Moreno-Rodriguez M, Perez S, Malek-Ahmadi M, Mufson E J Neuroinflammation. 2025; 22(1):25.

PMID: 39885546 PMC: 11783964. DOI: 10.1186/s12974-025-03349-y.

References

Duncan G, Plemel J, Assinck P, Manesh S, Muir F, Hirata R . Myelin regulatory factor drives remyelination in multiple sclerosis. Acta Neuropathol. 2017; 134(3):403-422. DOI: 10.1007/s00401-017-1741-7. View

Connick P, Kolappan M, Crawley C, Webber D, Patani R, Michell A . Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012; 11(2):150-6. PMC: 3279697. DOI: 10.1016/S1474-4422(11)70305-2. View

Almeida R, Lyons D . Oligodendrocyte Development in the Absence of Their Target Axons In Vivo. PLoS One. 2016; 11(10):e0164432. PMC: 5055324. DOI: 10.1371/journal.pone.0164432. View

Crawford A, Tripathi R, Foerster S, McKenzie I, Kougioumtzidou E, Grist M . Pre-Existing Mature Oligodendrocytes Do Not Contribute to Remyelination following Toxin-Induced Spinal Cord Demyelination. Am J Pathol. 2016; 186(3):511-6. PMC: 4816704. DOI: 10.1016/j.ajpath.2015.11.005. View

Lee S, Leach M, Redmond S, Chong S, Mellon S, Tuck S . A culture system to study oligodendrocyte myelination processes using engineered nanofibers. Nat Methods. 2012; 9(9):917-22. PMC: 3433633. DOI: 10.1038/nmeth.2105. View

Kotter M, Li W, Zhao C, Franklin R . Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci. 2006; 26(1):328-32. PMC: 6674302. DOI: 10.1523/JNEUROSCI.2615-05.2006. View

Gold R, Kappos L, Arnold D, Bar-Or A, Giovannoni G, Selmaj K . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367(12):1098-107. DOI: 10.1056/NEJMoa1114287. View

Cohen J, Coles A, Arnold D, Confavreux C, Fox E, Hartung H . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856):1819-28. DOI: 10.1016/S0140-6736(12)61769-3. View

Bunge M, Bunge R, RIS H . Ultrastructural study of remyelination in an experimental lesion in adult cat spinal cord. J Biophys Biochem Cytol. 1961; 10:67-94. PMC: 2225064. DOI: 10.1083/jcb.10.1.67. View

10.

Mei F, Lehmann-Horn K, Shen Y, Rankin K, Stebbins K, Lorrain D . Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife. 2016; 5. PMC: 5039026. DOI: 10.7554/eLife.18246. View

11.

Hutchinson M . Evoked potentials are of little use in the diagnosis or monitoring of MS: commentary. Mult Scler. 2013; 19(14):1824-5. DOI: 10.1177/1352458513506506. View

12.

Stankoff B, Freeman L, Aigrot M, Chardain A, Dolle F, Williams A . Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-¹¹C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol. 2011; 69(4):673-80. DOI: 10.1002/ana.22320. View

13.

Moyon S, Ma D, Huynh J, Coutts D, Zhao C, Casaccia P . Efficient Remyelination Requires DNA Methylation. eNeuro. 2017; 4(2). PMC: 5394940. DOI: 10.1523/ENEURO.0336-16.2017. View

14.

Moyon S, Huynh J, Dutta D, Zhang F, Ma D, Yoo S . Functional Characterization of DNA Methylation in the Oligodendrocyte Lineage. Cell Rep. 2016; 15(4):748-760. PMC: 5063656. DOI: 10.1016/j.celrep.2016.03.060. View

15.

MacKay A, Vavasour I, Rauscher A, Kolind S, Madler B, Moore G . MR relaxation in multiple sclerosis. Neuroimaging Clin N Am. 2008; 19(1):1-26. DOI: 10.1016/j.nic.2008.09.007. View

16.

Blakemore W, Franklin R . Remyelination in experimental models of toxin-induced demyelination. Curr Top Microbiol Immunol. 2008; 318:193-212. DOI: 10.1007/978-3-540-73677-6_8. View

17.

Sedel F, Bernard D, Mock D, Tourbah A . Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. 2015; 110(Pt B):644-653. DOI: 10.1016/j.neuropharm.2015.08.028. View

18.

Liddelow S, Guttenplan K, Clarke L, Bennett F, Bohlen C, Schirmer L . Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017; 541(7638):481-487. PMC: 5404890. DOI: 10.1038/nature21029. View

19.

Chen Y, Zhen W, Guo T, Zhao Y, Liu A, Rubio J . Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination. PLoS One. 2017; 12(12):e0189380. PMC: 5734789. DOI: 10.1371/journal.pone.0189380. View

20.

Rawji K, Yong V . The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol. 2013; 2013:948976. PMC: 3694375. DOI: 10.1155/2013/948976. View